Revista Colombiana de Reumatología (English Edition)最新文献

{"title":"Effect of induction therapy with mycophenolate or cyclophosphamide on serum BAFF levels in patients with systemic lupus erythematosus","authors":"Alejandra Betancur Herrera ,&nbsp;Juan José Mariño Restrepo ,&nbsp;Tulio Lopera Restrepo ,&nbsp;Laura Robledo Montoya ,&nbsp;Juan Felipe Soto Restrepo ,&nbsp;Adriana Lucía Vanegas García ,&nbsp;Carlos Horacio Muñoz Vahos ,&nbsp;Juan Camilo Díaz Coronado ,&nbsp;Ricardo Antonio Pineda Tamayo ,&nbsp;Gloria Vásquez","doi":"10.1016/j.rcreue.2024.12.002","DOIUrl":"10.1016/j.rcreue.2024.12.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which B cell hyperactivity plays a key role in its pathophysiology. In this disease, the B cell activating factor (BAFF) is implicated in the loss of immunological tolerance, and high concentrations of this factor have been linked to disease progression. It is unknown how induction therapies with cyclophosphamide (CFM) or mycophenolate (MMF) modulate BAFF levels.</div></div><div><h3>Objective</h3><div>To determine how induction therapies modulate BAFF concentrations.</div></div><div><h3>Materials and methods</h3><div>An analytical observational study was performed with 20 patients with SLE from two institutions between 2020–2022, clinical and laboratory information was obtained from medical records. Measurement of serum BAFF levels was performed using an ELISA kit and statistical analyses with GraphPad Prism version 9.</div></div><div><h3>Results</h3><div>20 patients with a diagnosis of SLE, 18 with CFM and 2 with MMF, were included, nine patients at baseline and eleven at 3–6 months. The median BAFF in SLE patients was 902.2 pg/mL and 379.7 pg/mL in healthy controls, statistically significant differences (p = .0003). BAFF levels were also found to be different among patients treated with antimalarials (p = .0465) and an inverse correlation with creatinine values and prednisolone doses was also observed.</div></div><div><h3>Conclusions</h3><div>BAFF levels are affected during induction therapy, observing an initial reduction and subsequent recovery at 3–6 months, our results suggest that chloroquine and high doses of prednisolone maintain lower serum BAFF levels.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 2","pages":"Pages 118-129"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with development of end stage renal disease during hospitalization in patients with microscopic polyangiitis and granulomatosis with polyangiitis in a population of northwestern Colombia","authors":"Santiago Cobaleda Cano ,&nbsp;Andrés Felipe Echeverri García ,&nbsp;Adriana Margarita Trejos Tenorio ,&nbsp;Javier Darío Márquez Hernández ,&nbsp;Jhon Edwar García Rueda ,&nbsp;Luis Fernando Pinto Peñaranda","doi":"10.1016/j.rcreue.2024.12.001","DOIUrl":"10.1016/j.rcreue.2024.12.001","url":null,"abstract":"<div><h3>Introduction</h3><div>ANCA vasculitis has been associated with increased morbidity and mortality, high disease burden, and organ damage, especially renal.</div></div><div><h3>Objectives</h3><div>To determine factors associated with end-stage kidney disease at hospital discharge in microscopic polyangiitis and granulomatosis with polyangiitis patients, to characterize our population, hospitalization causes, treatment received, and complications during stay.</div></div><div><h3>Materials and methods</h3><div>Adults with previous or new diagnosis of microscopic polyangiitis and granulomatosis with polyangiitis who required hospitalization between January 01, 2013, and April 30, 2021, were included. Association with end-stage kidney disease development was evaluated by Pearson’s Chi² (<em>χ</em>²) or Fisher’s test, and Student’s <em>t</em> or Mann–Whitney <em>U</em> test according to the nature of the variables. Exploratory multivariate models were made including factors associated with end-stage kidney disease.</div></div><div><h3>Results</h3><div>Forty-three patients were included, microscopic polyangiitis 55.8, and granulomatosis with polyangiitis 44.25. Twelve patients (27.9%) developed early end-stage kidney disease. High blood pressure, high urea nitrogen levels on admission, as well as pulmonary oedema, and Five Factor Score &gt;1 entailed a higher risk. In contrast, normal kidney function on admission was a protective factor. Rapidly progressive glomerulonephritis and arterial hypertension on admission were associated with end-stage kidney disease. In adjusted exploratory models according to vasculitis type, Birmingham Vasculitis Activity Score, diffuse alveolar haemorrhage, and plasma exchange use were identified as factors to include in multivariate models in multicentre studies.</div></div><div><h3>Conclusion</h3><div>88% of patients had renal involvement and 27.9% developed end-stage kidney disease. Rapidly progressive glomerulonephritis and arterial hypertension on hospital admission were associated with early development of end-stage kidney disease while normal renal function on admission was a protective factor for this outcome.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 1","pages":"Pages 16-26"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143444557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erdheim-Chester disease, an uncommon non-Langerhans cell histiocytosis and its association with Sjögren's syndrome","authors":"Alejandra Espinosa Trujillo ,&nbsp;Francisco Brañas Fernández ,&nbsp;Aitor Abuín Blanco ,&nbsp;Robustiano Pego Reigosa ,&nbsp;María Rodríguez Rodríguez","doi":"10.1016/j.rcreue.2024.11.002","DOIUrl":"10.1016/j.rcreue.2024.11.002","url":null,"abstract":"<div><div>Erdheim Chester disease (ECD) is a rare non-Langerhans cell histiocytosis. It is characterized by the infiltration of various organs and tissues by foamy histiocytes with a heterogeneous clinical course that varies from mild forms to disseminated forms with progressive and lethal behaviour. The case of a patient who presented with a cerebellar syndrome associated with autoimmune pathology is presented. In the course of the disease, refractoriness to glucocorticoids and clinical manifestation with bone involvement in the form of symmetrical osteosclerosis of long bones were determining factors for suspicion of this entity. We reviewed scientific articles through the PubMed metasearch engine with the keywords “erdheim chester disease”, “erdheim chester and nervous system”, and “autoimmunity and erdheim chester disease”, selecting those with greater emphasis on clinical presentation with neurological involvement and associated autoimmune pathology. Advances in the pathogenesis of ECD have allowed us to understand the nature of the disease, as well as the use of targeted therapies. It is interesting to keep this entity in mind, as well as the pathologies with which it is frequently associated, with the objective of an early diagnosis and a better clinical approach.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 1","pages":"Pages 90-94"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143444525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies for organizing rheumatology consultations","authors":"Juan Fernando Rivadeneira Jácome,&nbsp;Lara Montserrat González García","doi":"10.1016/j.rcreue.2024.11.006","DOIUrl":"10.1016/j.rcreue.2024.11.006","url":null,"abstract":"<div><h3>Introduction</h3><div>The prevalence of rheumatic disease in the general population is approximately 10%. At the same time, there has been an increase in the workload of rheumatology services, particularly concerning consultations. Many health institutions have limited the duration of rheumatology consultation to about 15 min. This article demonstrates the need to lengthen the duration rheumatology consultations.</div></div><div><h3>Objective</h3><div>The goal of this work is to review the literature about the standards for the duration of rheumatology consultations and to propose new organizational strategies in this regard.</div></div><div><h3>Materials and methods</h3><div>A narrative review of the current literature related to care standards in rheumatology consultations was carried out, including the wide variety of diagnostic procedures, which decisively influence the duration of these consultations.</div></div><div><h3>Results and discussion</h3><div>Organizational strategies are proposed, based on classifying consultations into first, second, and follow-up visits, with a specific daily number, and giving more time to the first two types of consultations. Although this planning implies greater effort on the part of administrative staff, it will undoubtedly result in a better quality of care for rheumatology patients.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 1","pages":"Pages 84-89"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143444611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum interleukin-41 concentrations are decreased in women with rheumatoid arthritis and are not affected by menopausal status, disease activity, or medication","authors":"Dhuha F.N. Bani-Wais ,&nbsp;Ali H. Ad’hiah","doi":"10.1016/j.rcreue.2025.02.002","DOIUrl":"10.1016/j.rcreue.2025.02.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Rheumatoid arthritis (RA) is an autoimmune inflammatory disorder characterized by immunobiological homeostasis. The recently discovered cytokine interleukin-41 (IL-41) is among the immunobiological components suggested to have modulatory effects in RA and has shown up-regulated levels in patients. However, IL-41 has not been explored during the pre- (PRM) and post-menopausal (POM) periods in women with RA, and its relationship to disease activity and medications has not been well studied.</div></div><div><h3>Materials and methods</h3><div>In this case–control study, serum IL-41 concentrations were quantified in 120 women with RA (70 PRM and 50 POM) and 110 control women using an enzyme-linked immunosorbent assay kit. Thirty patients were newly diagnosed (ND) and 90 patients were on treatment with etanercept (a tumor necrosis factor inhibitor; TNF) plus methotrexate (MD).</div></div><div><h3>Results</h3><div>Median IL-41 concentrations (interquartile range) were significantly lower in RA patients than in control women (49.8 [32.5–79.5] <em>vs</em>. 104.7 [76.9–134.6]<!--> <!-->pg/mL; probability &lt;.001). As indicated by the area under the curve, .827, IL-41 showed reliable discrimination between RA patients and HC. IL-41 concentrations stratified by menopausal status (PRM <em>vs</em>. POM), disease activity score 28 (&lt;3.2 <em>vs</em>. ≥3.2), and medication (ND <em>vs</em>. MD) showed no significant difference in each stratum.</div></div><div><h3>Conclusions</h3><div>In contrast to previous studies, serum IL-41 concentrations were significantly decreased in the present cohort of women with RA. These concentrations were not affected by menopausal status, disease activity, or medication. Data from the current study suggest that IL-41 is involved in the pathophysiology of RA.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 1","pages":"Pages 27-35"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143444558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic evidence of mepolizumab in eosinophilic granulomatosis with polyangiitis: A scoping review","authors":"Eduardo Tuta-Quintero ,&nbsp;Isabella Perna-Reyes ,&nbsp;Juan Olivella-Gómeza ,&nbsp;Daniela Rodríguez-Fraile ,&nbsp;Juan C. Santacruz ,&nbsp;Andrea A. Mayorga-Borja ,&nbsp;John Londoño","doi":"10.1016/j.rcreue.2024.11.008","DOIUrl":"10.1016/j.rcreue.2024.11.008","url":null,"abstract":"<div><div>Mepolizumab (MPZ) is a therapeutic option for eosinophilic granulomatosis with polyangiitis (EGPA). However, the evidence on its efficacy, effectiveness, and safety is limited. Our results included 17 full-text articles evaluating the use of MPZ in patients diagnosed with EGPA, 47% (8/17) of the documents were case reports, 18% (3/17) retrospective cohort studies, 12% (2/17) clinical trials, and 6% corresponded to a prospective cohort (1/17), ambispective cohort (1/17), case series (1/17), and pilot study (1/17). The most frequently used dose of MPZ was 300 mg/month, described in 59% (10/17) of the included manuscripts. The decrease in the Birmingham Vasculitis Activity Score, reduction in the dose of corticosteroids, and modulation in the number of eosinophils in the blood were the variables most used to determine the clinical effect in patients. Finally, 10 clinical trial records were included describing the design, conduct, and administration of the ongoing studies. The use of MPZ in patients with EGPA shows a reduction in the Birmingham Vasculitis Activity Score, saving oral corticosteroids and modulating blood hypereosinophilia. The adverse events described were mild and moderate in all the included studies.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 1","pages":"Pages 69-83"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143444610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus for risk management in the prescription of biologic therapies or targeted synthetic antirheumatic drugs: Colombian Association of Rheumatology 2023","authors":"Elías Gonzalo Forero Illera ,&nbsp;Andrés Ricardo Fernández Aldana ,&nbsp;Daniel Gerardo Fernández Ávila ,&nbsp;Edwin Antonio Jáuregui Cuartas ,&nbsp;Gloria Vásquez ,&nbsp;Monique Chalem ,&nbsp;Wilson Bautista Molano","doi":"10.1016/j.rcreue.2024.11.005","DOIUrl":"10.1016/j.rcreue.2024.11.005","url":null,"abstract":"","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 1","pages":"Pages 56-68"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143444609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of rheumatic patients who consult digital information sources","authors":"Maria Pía Izaguirre Germain ,&nbsp;Paola Ávila ,&nbsp;Nauan Fara ,&nbsp;Julia Pretini ,&nbsp;María Elena Gaona ,&nbsp;Pia Pissani ,&nbsp;Maira Arias Saavedra ,&nbsp;Valeria Aquino ,&nbsp;Mariana Espindola Echazu ,&nbsp;Manuela Laffont ,&nbsp;Magdalena Acevedo ,&nbsp;Lucrecia Garcia Faura ,&nbsp;Romina Hassan ,&nbsp;Karen Roberts ,&nbsp;Jorge Alejandro Brigante ,&nbsp;Damaris Álvarez ,&nbsp;Marina Laura Micelli ,&nbsp;Vanesa Laura Cosentino ,&nbsp;Sandra Fabiana Montoya ,&nbsp;Gabriel Sequeira ,&nbsp;Eduardo Mario Kerzberg","doi":"10.1016/j.rcreue.2024.11.003","DOIUrl":"10.1016/j.rcreue.2024.11.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Many patients use the internet as a source of health information and to create and share content of diverse quality of evidence, complementing and even competing with traditional sources of information.</div></div><div><h3>Objectives</h3><div>To evaluate differences between rheumatic patients who consult digital information sources (DISs) and those who do not (Non-DISs), and their perception of the credibility attributed to these sources by both groups.</div></div><div><h3>Materials and Methods</h3><div>An observational cross-sectional study was conducted through an anonymous survey of patients with rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and spondyloarthritis. Patients were asked about their search for information from different DISs or Non-DISs. Patients rated the credibility they assigned to the different sources on a scale of 0–10, where 0 was no credibility and 10 was the maximum possible credibility.</div></div><div><h3>Results</h3><div>A total of 402 patients (79% female) were surveyed. Two hundred and seven (51%) had consulted at least one DIS during the previous year (DISs group). The DISs group had consulted a total of 5 DISs and Non-DISs (First-Third Quartile: 3–7) vs. 2 (First-Third Quartile: 1–3) in the Non-DISs group (<em>P</em> &lt; .001). The number of searches in DISs was higher at younger ages (OR .97 95% CI .95–.99) and at higher levels of education (secondary vs. primary OR 2.0; 95% CI 1.05–3.85). The DISs group assigned higher credibility to Facebook and YouTube than the other patients (median credibility of 6/10 and 6/10 vs. 2/10 and 1/10 respectively; <em>P</em> &lt; .001). However, they did not assign lower credibility to traditional sources.</div></div><div><h3>Conclusions</h3><div>DISs are more frequently consulted by a younger population with a higher level of education. These patients consult multiple sources, but do not assign lower credibility to traditional information sources.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 1","pages":"Pages 43-48"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143444607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical convergence: An exceptional case of sarcoidosis and tuberculosis with multiple organic manifestations. Case report","authors":"Néstor Correa-González ,&nbsp;María Claudia Díaz ,&nbsp;Keyla Jemihah Triana Ángel ,&nbsp;María Daniela Polania ,&nbsp;Natalia Remolina Murillo ,&nbsp;Pilar Alarcón Robles","doi":"10.1016/j.rcreue.2024.11.004","DOIUrl":"10.1016/j.rcreue.2024.11.004","url":null,"abstract":"<div><h3>Introduction</h3><div>The diagnosis of sarcoidosis is challenging, especially if the patient has concomitant infectious symptoms. Furthermore, the overlap of immune-mediated and infectious pathologies is not uncommon.</div></div><div><h3>Objective</h3><div>To report a rare case of association between tuberculosis and sarcoidosis</div></div><div><h3>Materials and methods</h3><div>Description of the clinical characteristics of a patient who presented with sarcoidosis superimposed on tuberculosis.</div></div><div><h3>Results</h3><div>The case of a 29-year-old man with ocular, cutaneous, and systemic symptoms is described. Uveitis and chronic non-caseating granulomatous findings were diagnosed in the skin, lungs, and lymph nodes. Suspicion of tuberculosis led to positive molecular biology tests only in the lymph node biopsy. An overlap of sarcoidosis and tuberculosis was determined, and combined treatment with glucocorticoids and anti-tuberculosis agents was initiated, resulting in improvement of the patient.</div></div><div><h3>Conclusions</h3><div>Sarcoidosis and tuberculosis share characteristics from their aetiology to clinical manifestations, posing a challenge in clinical differentiation. Cases have been documented where both diseases overlap in the same patient.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 1","pages":"Pages 95-102"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143444526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relative gene expression levels of the gene coding for monocyte chemoattractant protein-1 (MCP-1) as a urinary biomarker in lupus nephropathy","authors":"Esther Casablanca Alarcón ,&nbsp;Mabel de la Cruz Mendoza ,&nbsp;María de los Ángeles Terán de Baudoin ,&nbsp;Rolando Pastén Vargas ,&nbsp;Manuel Montero Jauregui ,&nbsp;Carlos Guachalla Castro ,&nbsp;Luis Fernando Sosa Tordoya","doi":"10.1016/j.rcreue.2024.11.007","DOIUrl":"10.1016/j.rcreue.2024.11.007","url":null,"abstract":"<div><h3>Introduction</h3><div>Lupus nephropathy (LN) is a chronic inflammatory process, characterized by the activation of T cells and high levels of various cytokines, such as MCP-1 at the level of the renal glomerulus and the interstitial tubule. MCP-1 is a chemoattractant of monocytes and lymphocytes, it is responsible for the infiltration of leukocytes in the kidney, which is why MCP-1 levels in urine of patients with LN correlate with the active form of the disease.</div></div><div><h3>Objective</h3><div>The present study aims to evaluate the expression levels of MCP-1 in patients with LN and to correlate their urinary levels with serum autoimmunity markers.</div></div><div><h3>Material and methods</h3><div>Our study is of the case-control type, where the groups were made up of 112 patients diagnosed with SLE or LN, and 28 apparently healthy people with no clinical or family history of autoimmune diseases, respectively. MCP-1 expression levels were estimated using qRT-PCR. In addition, clinical parameters and serum levels were evaluated (anti-ds-DNA, anti-nucleosome, anti-C1q antibodies, β2-microglobulin levels, and C3 and C4 complement fraction). Finally, clinical, and molecular data were correlated.</div></div><div><h3>Results</h3><div>Our study included 39 patients with active SLE (median 36 years), 32 with active LN (median 32.5 years), 28 with inactive SLE (median 41.5 years), 13 with inactive LN (median 38 years), and 28 control patients (median 28.5 years). The comparison of MCP-1 expression levels between patients with active LN and active SLE did not show statistically significant values (<em>p</em> &gt; 0.05). Likewise, a statistically significant correlation was observed between the expression levels of MCP-1 with the levels of anti-C1q (<em>r</em> = 0.255 <em>p</em> &lt; 0.025); however, no correlation was found with the other markers.</div></div><div><h3>Conclusion</h3><div>The use of MCP-1 expression levels in the Bolivian population would not be a useful biomarker to evaluate Lupus Nephropathy. However, the anti-C1q biomarker is suggested as a serological marker for monitoring the disease.</div></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"32 1","pages":"Pages 49-55"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143444608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}